REDEFINE 5 adds an active-comparator study in a defined regional and clinical setting. Location and eligibility describe the evidence's context; they should not become simplistic claims about ancestry determining response. Primary trial
Trial findings
The double-blind 68-week phase 3a trial compared cagrilintide–semaglutide with semaglutide in Japan and Taiwan. Participants met specified BMI and complication criteria, with or without type 2 diabetes. Estimated weight change was −18.4% with the combination and −11.9% with semaglutide. Gastrointestinal disorders were the most common adverse events. Novo Nordisk funded the trial. Primary trial
Our appraisal: an active comparator changes the question
This comparison asks about the tested combination relative to a specified active strategy. It is not a placebo comparison, and its difference should not be substituted for one. Background lifestyle intervention and the comparator regimen are part of the treatment context.
Eligibility also matters. A study conducted in a region does not automatically represent every person living there. Recruitment setting, age, disease severity, concurrent conditions, and other selection criteria help determine applicability.
Our fuller review would examine analysis populations, diabetes-stratified results if prespecified, treatment discontinuation, missing measurements, and complete safety reporting. If subgroups are discussed, their precision and interaction analyses should remain visible rather than assuming that the overall estimate applies identically to each subgroup.
Frequently asked questions
Was placebo the comparator?
No. Semaglutide was the active comparator.
Were only patients with diabetes enrolled?
The eligibility allowed participants with or without type 2 diabetes.
Does a regional trial establish an ancestry-based response rule?
No. Recruitment context and individual characteristics need careful interpretation.
Can the active-comparator difference be called a placebo difference?
No. That would change the comparison.
Does the result establish the effect of every combination formulation?
No. The tested preparation and conditions remain essential.
Does this provide a personal regimen?
No.
What is the review scope?
The primary indexed abstract. Full population, analysis, safety, registry, and correction checks remain pending.